Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin + AVD in Indian Patients with Untreated Stage 3/4 Classical Hodgkin Lymphoma
NCT06831370Phase 4Recruiting
- Sponsor
- Takeda
- Start
- Aug 2024
- Primary completion
- Mar 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of brentuximab vedotin in classical Hodgkin lymphoma (cHL), sponsored by Takeda. Started Aug 2024; status: recruiting.
02
Drugs
brentuximab vedotin
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT06831370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06831370.